In a rarely seen move, a small-cap British Columbia-based cannabis company is ending its time on the Canadian Securities Exchange (CSE) with a voluntary delisting application.

ICC International Cannabis (ICC) (CSE:WRLD.U,OTC Pink:WLDCF) told investors on Wednesday (December 18) that it’s looking to pull its common shares off the exchange after assessing alternatives to preserve its operations and expand its business activities.


“In the course of its review process, the company has determined that certain funding opportunities at valuations that better reflect the underlying asset value of the company are only available should the company become a non-listed reporting issuer,” ICC said in a statement.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

ICC’s review into its business also looked into cost-cutting measures in an effort to maintain its capital position.

The firm said it received consent for the delisting from a majority group of minority shareholders from the company. This group excludes company executives with a stake in ICC.

The application is now subject to final approval from the CSE, but before the delisting is signed off, ICC will continue as a reporting issuer on the exchange in certain jurisdictions in Canada.

ICC did not respond to a request from the Investing News Network for further comment.

In a press release, the company said it plans to evaluate alternative liquidity for its shareholders in 2020, including a reverse takeover, a direct listing, an asset or trade sale or entering into a joint venture.

According to the CSE’s delisting policy, an issuer has the right to request any or all of its securities are delisted, but the exchange is free to reject the application if it’s owed outstanding fees or if the request is made so that the company can proceed with a transaction the CSE deems “unacceptable” or “objectionable.” The CSE can also deny the request if it believes it’s in the public interest to do so.

Barrington Miller, director of listed company services at the CSE, told the Investing News Network (INN) that applications are rejected if the delisting could negatively impact the shareholders of the company in question.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Delisting applications are reviewed by a listing committee on a case-by-case basis, Miller said.

“The number of companies to voluntarily delist to go private is few and far between,” he told INN, adding that the small number of firms that do decide to take their shares off of the CSE often do so after obtaining listings on other exchanges.

The firm boasts of cannabis operation assets in Europe, Asia, Africa and South America. ICC holds an investment relationship with Auxly Cannabis Group (TSXV:XLY,OTCQX:CBWTF), which subscribed for C$5 million of senior unsecured convertible debentures of ICC in 2018.

ICC was last active on its Facebook and Twitter accounts in July to announce a cannabinoid pharmaceutical advisory agreement with Dr. Alexandros Makriyannis an advisor, according to the firm, with Pfizer (NYSE:PFE), Bristol-Myers Squibb (NYSE:BMY) and other players in the pharma industry.

Shares of ICC opened at US$0.20 at the market open on Wednesday and dipped to US$0.10 nearing the end of the trading session. Year-to-date, the company has experienced massive losses, plunging 96.2 percent.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Danielle Edwards, hold no direct investment interest in any company mentioned in this article.

Editorial Disclosure: The Investing News Network does not guarantee the accuracy or thoroughness of the information reported in the interviews it conducts. The opinions expressed in these interviews do not reflect the opinions of the Investing News Network and do not constitute investment advice. All readers are encouraged to perform their own due diligence.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Appointment of Dr. Kelmendi, Assistant Professor of Psychiatry at Yale University and co-founder of the Yale Psychedelic Science Group, brings another experienced medical professional to Lobe’s advisory team.

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the appointment of Benjamin Kelmendi, MD, Assistant Professor of Psychiatry at Yale University School of Medicine, to its Scientific Advisory Board.

Keep reading... Show less

Ayurcann Holdings Corp. ( CSE: AYUR ) (the “ Company ” or ” Ayurcann “), a Canadian extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, is pleased to unveil further details of its Phase 2 expansion plans.

Ayurcann has commenced trading on the Canadian Securities Exchange (” CSE “) on April 8, 2021 and subsequently announced a private placement of up to $500,000 (” Financing “), as per the Company’s press release dated April 12, 2021. The proceeds of the Financing are intended to be used to further pursue Phase 2 of the expansion of the production capacity of the Company’s Pickering facility.

Keep reading... Show less

New findings suggest the COVID-19 pandemic, combined with expanded state legalization, has attracted new consumers to the category and accelerated cannabis acceptance and adoption.

  • YouGov study indicates the number of current cannabis consumers has increased 56% within just two years compared to the 16% of Americans who reported current consumption in 2018.
  • 23% of current consumers say they tried cannabis for the first time within the past year.
  • More than half of cannabis consumers say they will purchase or try a new product or format this 420, indicating that the holiday is becoming increasingly focused on exploration and trial.

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or the “Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, released the results of a survey today showing one in four Americans currently consume cannabis, reporting they’ve tried some form of cannabis within the past twelve months. That’s a significant increase since 2018* when just 16% of U.S. adults reported current consumption, representing a 56% increase in just two years. What’s more, 23% of current cannabis consumers say they tried cannabis for the first time over the past year, suggesting the COVID-19 pandemic, combined with expanded state legalization, has rapidly accelerated cannabis acceptance and adoption in America.

Keep reading... Show less

Acquires Three Operating Dispensaries in Northeast Pennsylvania

Purchase price represents a mid-single digit multiple of KCR’s expected 2021 EBITDA

Keep reading... Show less